Workflow
Hangzhou Alltest Biotech (688606)
icon
Search documents
奥泰生物(688606) - 关于股份回购进展公告
2026-03-31 09:22
杭州奥泰生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 回购方案首次披露日 | 2026/1/22 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 9 2 月 8 | 月 | 日~2027 | 年 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 1,311,010股 | | | | | | 累计已回购股数占总股本比例 | 1.65% | | | | | | 累计已回购金额 | 85,903,234.32元 | | | | | | 实际回购价格区间 | 62.35元/股~68.29元/股 | | | | | 一、回购股份的基 ...
奥泰生物(688606) - 关于股份回购进展公告
2026-03-23 08:46
一、回购股份的基本情况 证券代码:688606 证券简称:奥泰生物 公告编号:2026-015 杭州奥泰生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 回购方案首次披露日 | 2026/1/22 | | | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 月 9 日~2027 年 | 2 月 8 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | 累计已回购股数 | 1,129,610股 | | | 累计已回购股数占总股本比例 | 1.42% | | | 累计已回购金额 | 74,432,660.41元 | | | 实际回购价格区间 | 62.62元/股~68.29元/股 | | 杭州奥泰生物技术股份有限公司董事会 2026 年 3 月 24 日 杭州奥泰生物技术股份有限 ...
奥泰生物(688606) - 关于以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告
2026-03-18 09:16
| 回购方案首次披露日 | 2026/1/22 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 月 9 日~2027 年 | 2 | 月 8 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 820,510股 | | | | 累计已回购股数占总股本比例 | 1.03% | | | | 累计已回购金额 | 54,509,397.69元 | | | | 实际回购价格区间 | 64.05元/股~68.29元/股 | | | 一、回购股份的基本情况 杭州奥泰生物技术股份有限公司 关于以集中竞价交易方式回购公司股份比例达到 1% 暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 杭州奥泰生物技术股份有限公司(以下简称"公司")于 20 ...
奥泰生物(688606) - 关于首次回购股份暨回购进展的公告
2026-03-02 08:30
证券代码:688606 证券简称:奥泰生物 公告编号:2026-013 杭州奥泰生物技术股份有限公司 关于首次回购股份暨回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 回购方案首次披露日 | 2026/1/22 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 9 月 8 日 | 月 | 日~2027 | 年 | 2 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 11.70万股 | | | | | | 累计已回购股数占总股本比例 | 0.15% | | | | | | 累计已回购金额 | 787.69万元 | | | | | | 实际回购价格区间 | 66. ...
杭州奥泰生物技术股份有限公司2025年度业绩快报公告
Core Viewpoint - The company reported a total revenue of 911.30 million RMB for the year 2025, reflecting a growth of 5.16% compared to the previous year, but net profit decreased by 27.83% due to various cost pressures and increased expenses [2][3]. Financial Performance and Condition - The company achieved total revenue of 911.30 million RMB, a 5.16% increase year-on-year - Net profit attributable to shareholders was 218.28 million RMB, down 27.83% from the previous year - Net profit excluding non-recurring gains and losses was 155.25 million RMB, a decline of 34.64% compared to the previous year - Total assets at the end of the reporting period were 4,248.62 million RMB, up 1.50% from the beginning of the period - Shareholders' equity attributable to the parent company was 3,944.50 million RMB, an increase of 1.57% from the beginning of the period [2]. Factors Affecting Performance - The company maintained competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume - Increased investment in new technology platforms and efforts in domestic and international market registrations led to higher R&D and sales costs - Additional factors impacting profit included increased operating costs due to U.S. tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and increased asset depreciation [2][3]. Significant Changes in Financial Metrics - Despite a revenue increase of 5.16%, the overall profitability was pressured by declining product prices, rising sales, management, and R&D expenses, as well as increased financial costs - Key financial metrics such as operating profit, total profit, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses all saw declines of 27.72%, 28.36%, 27.83%, and 34.64% respectively compared to the previous year [3].
奥泰生物:2025年度业绩快报公告
Zheng Quan Ri Bao· 2026-02-27 13:37
Group 1 - The company announced a projected total operating revenue of 911.30 million yuan for the fiscal year 2025, representing a year-on-year growth of 5.16% [2] - The net profit attributable to the owners of the parent company is expected to be 218.28 million yuan [2]
奥泰生物(688606.SH):2025年度净利润2.18亿元,同比下降27.83%
Ge Long Hui A P P· 2026-02-27 10:43
Core Viewpoint - The company reported a total operating revenue of 911 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 5.16%. However, the net profit attributable to the parent company decreased by 27.83% to 218 million yuan, and the net profit after deducting non-recurring gains and losses fell by 34.64% to 155 million yuan [1]. Group 1: Financial Performance - The total operating revenue for 2025 was 911 million yuan, an increase of 5.16% compared to the previous year [1]. - The net profit attributable to the parent company was 218 million yuan, a decrease of 27.83% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 155 million yuan, down 34.64% from the previous year [1]. Group 2: Factors Affecting Performance - The company maintained its competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume [1]. - Increased investment in new technology platform R&D and efforts in domestic and international market and product registration led to a rise in R&D and sales costs compared to the previous year [1]. - Additional factors contributing to the profit decline included increased operating costs due to U.S. government tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and increased asset depreciation and amortization [1].
奥泰生物:2025年度净利润2.18亿元,同比下降27.83%
Ge Long Hui· 2026-02-27 10:34
Core Viewpoint - The company reported a total operating revenue of 911 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 5.16%. However, the net profit attributable to the parent company decreased by 27.83% to 218 million yuan, and the net profit after deducting non-recurring gains and losses fell by 34.64% to 155 million yuan [1]. Group 1: Financial Performance - The total operating revenue for 2025 was 911 million yuan, an increase of 5.16% compared to the previous year [1]. - The net profit attributable to the parent company was 218 million yuan, a decrease of 27.83% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 155 million yuan, down 34.64% from the previous year [1]. Group 2: Factors Affecting Performance - The company maintained its competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume [1]. - Increased investment in new technology platforms and efforts in domestic and international market and product registrations led to a rise in R&D and sales costs compared to the previous year [1]. - Additional factors contributing to the decline in profit included increased operating costs due to U.S. government tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and higher asset depreciation and amortization [1].
奥泰生物(688606) - 2025 Q4 - 年度业绩
2026-02-27 09:00
Financial Performance - Total revenue for 2025 reached RMB 91,130.05 million, representing a 5.16% increase compared to the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 21,828.01 million, a decrease of 27.83% year-on-year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 15,524.62 million, down 34.64% from the previous year[3] - Operating profit decreased by 27.72% to RMB 24,974.78 million compared to the previous year[3] - Basic earnings per share decreased by 28.01% to RMB 2.75[3] - The weighted average return on net assets decreased by 2.23 percentage points to 5.58%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 424,862.06 million, an increase of 1.50% from the beginning of the period[4] - Shareholders' equity attributable to the parent company increased by 1.57% to RMB 394,449.65 million[4] Cost and Investment Factors - The decline in profitability was attributed to increased R&D and sales costs, product price declines, and rising financial expenses[6][7] - The company continues to invest in new technology platforms and expand domestic and international market registrations[5]
奥泰生物:2025年净利润同比减少27.83%
Core Insights - The company reported a revenue of 911 million yuan for the fiscal year 2025, representing a year-on-year growth of 5.16% [1] - The net profit attributable to shareholders decreased to 218 million yuan, reflecting a year-on-year decline of 27.83% [1] - The basic earnings per share (EPS) fell to 2.75 yuan, down 28.01% compared to the previous year [1]